CABOSUN, 2017 trial summary

A randomised clinical trial investigating the effect of cabozantinib versus sunitinib in untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria

Studied treatment	cabozantinib (60 mg once per day)
Control treatment	sunitinib (50 mg once per day; 4 weeks on, 2 weeks off).

Patients	untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria
Group sizes	79 / 78
treatment line
cross over

Blindness	open-label	Inclusion period
Follow-up duration		Centers
Lost to FU		geographical localisation
Primary endpoint	PFS	Design	Parallel groups

phase 2

Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol 2017;35:591-597 [PMID: 28199818] link to pdf add to Mendeley

ClinicalTrial.gov record NCT01835158

Registering number	NCT01835158 (see trial on clinicaltrials.gov)
Code Name	Alliance A031203